Clinical Trial Update: Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial evaluating rituximab for fibrillary glomerulonephritis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrillary Glomerulonephritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Fibrillary Glomerulonephritis | Phase 2 | Status: COMPLETED | Results posted: 2019-02-06